Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
19
PSTV Quote, Financials, Valuation and Earnings
Last price:
$0.38
Seasonality move
:
-14.32%
Day range:
$0.32 - $0.34
52-week range:
$0.16 - $2.31
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.53x
P/B ratio:
--
Volume:
3.9M
Avg. volume:
45.2M
1-year change:
-82.86%
Market cap:
$10.6M
Revenue:
--
EPS (TTM):
-$2.94
Analysts' Opinion
-
Consensus RatingPlus Therapeutics has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.17, Plus Therapeutics has an estimated upside of 2729.22% from its current price of $0.32.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 100% downside risk from its current price of $0.32.
Fair Value
-
According to the consensus of 2 analysts, Plus Therapeutics has 2729.22% upside to fair value with a price target of $9.17 per share.
PSTV vs. S&P 500
-
Over the past 5 trading days, Plus Therapeutics has underperformed the S&P 500 by -8.22% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Plus Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Plus Therapeutics revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Plus Therapeutics reported revenues of --.
Earnings Growth
-
Plus Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Plus Therapeutics reported earnings per share of -$1.19.
Enterprise value:
733.3K
EV / Invested capital:
--
Price / LTM sales:
0.53x
EV / EBIT:
--
EV / Revenue:
0.12x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.06x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$20.5M | -$11.9M | -$14.9M | -$3.3M | -$3.5M | |
| EBITDA | -$19.7M | -$10.9M | -$22.2M | -$3.1M | -$16.7M | |
| Diluted EPS | -$10.84 | -$3.04 | -$2.94 | -$0.75 | -$1.19 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $15.4M | $22.1M | $13.6M | $4.2M | $10.9M | |
| Total Assets | $18.3M | $24.5M | $15.6M | $5.6M | $12.1M | |
| Current Liabilities | $8.3M | $4.9M | $12.8M | $10.4M | $10.6M | |
| Total Liabilities | $8.8M | $9.9M | $13M | $10.5M | $35.7M | |
| Total Equity | $9.5M | $14.6M | $2.7M | -$4.8M | -$23.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$14.9M | -$11.6M | -$12.2M | -$4.5M | -$6.2M | |
| Cash From Investing | -$279K | -$427K | -$189K | -$364K | $3.6M | |
| Cash From Financing | $6.7M | $2.2M | $19.4M | -$776K | $12.4M | |
| Free Cash Flow | -$15.2M | -$11.7M | -$12.9M | -$4.6M | -$6.2M | |
PSTV
Sector
Market Cap
$10.6M
$34.4M
Price % of 52-Week High
14.03%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-82.86%
-37.36%
Beta (5-Year)
0.693
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.33
200-day SMA
Sell
Level
$0.95
Bollinger Bands (100)
Sell
Level
0.28 - 0.98
Chaikin Money Flow
Sell
Level
-47.4M
20-day SMA
Buy
Level
$0.30
Relative Strength Index (RSI14)
Sell
Level
48.25
ADX Line
Buy
Level
30.14
Williams %R
Neutral
Level
-63.756
50-day SMA
Sell
Level
$0.37
MACD (12, 26)
Buy
Level
0.09
25-day Aroon Oscillator
Buy
Level
16
On Balance Volume
Neutral
Level
106.1M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Stock Forecast FAQ
In the current month, PSTV has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The PSTV average analyst price target in the past 3 months is $9.17.
-
Where Will Plus Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Plus Therapeutics share price will rise to $9.17 per share over the next 12 months.
-
What Do Analysts Say About Plus Therapeutics?
Analysts are divided on their view about Plus Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Plus Therapeutics is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is Plus Therapeutics's Price Target?
The price target for Plus Therapeutics over the next 1-year time period is forecast to be $9.17 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is PSTV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Plus Therapeutics is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of PSTV?
You can purchase shares of Plus Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Plus Therapeutics shares.
-
What Is The Plus Therapeutics Share Price Today?
Plus Therapeutics was last trading at $0.38 per share. This represents the most recent stock quote for Plus Therapeutics. Yesterday, Plus Therapeutics closed at $0.32 per share.
-
How To Buy Plus Therapeutics Stock Online?
In order to purchase Plus Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
